Loading...
01/11 15:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance, with record high operating cash flow and free cash flow, along with positive trends in MACI Arthro demand and surgeon adoption. The Q&A session reveals positive analyst sentiment, with no significant insurance challenges reported. The company's MACI sales force expansion and expected profitability improvements further support a positive outlook. However, cautious guidance for Q4 and lack of specific 2026 projections slightly temper enthusiasm. Overall, the sentiment is positive, with potential for a stock price increase in the 2% to 8% range.
Total Revenue $67.5 million for Q3 2025, a record high. This represents a significant increase driven by strong performance across all product lines.
MACI Revenue $55.7 million for Q3 2025, a 25% year-over-year increase. Growth attributed to expanding the MACI surgeon base, increased biopsies, and the launch of MACI Arthro.
Burn Care Revenue $11.8 million for Q3 2025, a 21% sequential increase from Q2 2025. Epicel revenue reached $10.4 million, its highest quarter of the year, and NexoBrid revenue was $1.5 million, a 38% year-over-year increase.
Gross Profit Nearly $50 million for Q3 2025, representing 73.5% of revenue. This reflects significant margin expansion due to strong revenue growth.
GAAP Net Income $5.1 million for Q3 2025. This marks a notable profit growth driven by revenue increases and operational efficiency.
Adjusted EBITDA $17 million for Q3 2025, a nearly 70% year-over-year increase, representing 25% of revenue. This reflects improved profitability and operational leverage.
Operating Cash Flow $22.1 million for Q3 2025, a record high. This was driven by strong revenue and profit growth, along with lower capital expenditures.
Free Cash Flow Nearly $20 million for Q3 2025. This was achieved with $2.6 million in capital expenditures, reflecting efficient cash management.
MACI Arthro: Early launch indicators are very strong, contributing to overall biopsy and implant growth. Over 800 surgeons trained by October, with higher growth rates for trained surgeons. Early data suggests improved patient outcomes, including reduced postsurgical pain and shorter recovery times.
NexoBrid: Achieved its highest quarterly revenue since launch, growing 38% year-over-year and 26% quarter-over-quarter.
MACI OUS Expansion: Initiating a phased approach to expand MACI outside the U.S., starting with the U.K. A marketing application is expected mid-next year, with a potential launch in the first half of 2027.
Revenue Growth: Record total revenue of $67.5 million in Q3, with MACI revenue growing 25% to $55.7 million and Burn Care revenue increasing 21% sequentially.
Profitability: GAAP net income of $5.1 million, adjusted EBITDA margin of 25%, and record operating cash flow of $22.1 million in Q3.
Sales Force Expansion: On track to complete MACI sales force expansion in Q4, supporting significant volume growth and positioning for strong performance in 2026.
MACI Ankle Clinical Study: Phase III study to be initiated this quarter, representing a substantial growth opportunity to expand into other orthopedic markets.
New Manufacturing Facility: Commercial manufacturing for MACI in the new facility to begin next year, designed to meet U.S. and global requirements, enabling potential commercialization outside the U.S.
Regulatory Risks: The company is planning to expand MACI into the U.K. market, which involves regulatory approvals and submission of a marketing application. Any delays or issues in obtaining these approvals could impact the timeline and success of the expansion.
Supply Chain and Manufacturing Risks: The company is initiating commercial manufacturing for MACI in a new facility next year. Any disruptions or delays in this process could affect production and the ability to meet both U.S. and global manufacturing requirements.
Market Expansion Risks: The planned MACI launch in the U.K. and potential commercialization outside the U.S. depend on successful execution of the expansion strategy. Failure to achieve market penetration or acceptance in new regions could limit growth opportunities.
Sales Force Expansion Challenges: The company is expanding its MACI sales force, which involves training and operational adjustments. Any inefficiencies or delays in this process could impact sales performance and operational execution.
Economic and Competitive Pressures: While MACI is a market leader, maintaining its competitive position requires continued investment in sales, marketing, and clinical data generation. Economic uncertainties or increased competition could pressure margins and growth.
MACI Revenue Growth: MACI revenue is expected to grow by low 20% for the full year 2025, with fourth quarter revenue projected at approximately $82 million to $84 million. MACI's revenue growth is anticipated to accelerate from 18% in the first half of the year to approximately 23% in the second half.
Burn Care Revenue: Full year revenue for Burn Care is expected to be approximately $34.5 million to $36.5 million, with fourth quarter revenue projected at $6.5 million to $8.5 million. Epicel trends in Q4 are expected to be similar to Q4 of last year.
Profitability Targets: The company reaffirms its full-year profitability guidance of gross margin at 74% and adjusted EBITDA margin at 26%. For Q4, gross margin is expected to be approximately 77%, with adjusted EBITDA margin of approximately 40%.
MACI Arthro Expansion: The company plans to continue expanding the number of MACI Arthro trained surgeons in 2026, building on the current base of over 800 trained surgeons. This expansion is expected to drive further biopsy and implant growth.
MACI Ankle Clinical Study: The Phase III MACI Ankle clinical study is set to begin in Q4 2025, representing a significant growth opportunity to expand into other orthopedic markets.
MACI Manufacturing and OUS Expansion: Commercial manufacturing for MACI in the new facility is expected to begin in 2026, designed to meet U.S. and global requirements. The company plans to launch MACI in the U.K. in the first half of 2027, targeting a substantial international growth opportunity.
Midterm Profitability Goals: The company aims to achieve gross margins in the high 70% range and adjusted EBITDA margins in the high 30% range by 2029.
The selected topic was not discussed during the call.
The earnings call highlights strong financial performance, with record high operating cash flow and free cash flow, along with positive trends in MACI Arthro demand and surgeon adoption. The Q&A session reveals positive analyst sentiment, with no significant insurance challenges reported. The company's MACI sales force expansion and expected profitability improvements further support a positive outlook. However, cautious guidance for Q4 and lack of specific 2026 projections slightly temper enthusiasm. Overall, the sentiment is positive, with potential for a stock price increase in the 2% to 8% range.
The earnings call shows strong financial performance with record revenue growth and narrowed net loss, despite a slight miss in MACI's Q2 guidance. Optimistic guidance and improvements in profitability metrics, along with strategic expansions in sales force and international markets, suggest positive sentiment. The Q&A section highlights potential risks but also reinforces confidence in future growth, particularly in MACI and NexoBrid segments. Overall, the positive aspects outweigh the negatives, suggesting a likely stock price increase.
The earnings call presents mixed signals: strong revenue growth and promising product developments are offset by missed EPS expectations, increased operating expenses, and revenue variability in key areas like Epicel. The Q&A section reveals some optimism, but also highlights uncertainties regarding MACI Arthro's impact and competitive pressures. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the stock price is likely to remain stable, with no significant movement expected over the next two weeks.
The earnings call presents a mixed picture. Strong revenue growth and optimistic guidance for 2025 are positives. However, challenges like Epicel revenue variability, increased operating expenses, and lack of shareholder return plans are concerning. The Q&A revealed uncertainties about MACI Arthro's impact and market expansion, contributing to a neutral sentiment. Without a market cap, stock volatility cannot be precisely gauged, but the absence of significant catalysts suggests a neutral outlook in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
